Effect of Al-chlorophenoxyisobutyrate (Alufibrate) on pyruvate metabolism and on the fate of very low density lipoprotein lipids in hyperlipidemic patients.
D000328:Adult; D000535:Aluminum / Q000494:pharmacology / Q000627:therapeutic use; D002087:Butyrates / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000378:metabolism; D002250:Carbon Radioisotopes; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D004586:Electrophoresis; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010647:Phenyl Ethers / Q000627:therapeutic use; D011134:Polysaccharides; D011773:Pyruvates / Q000378:metabolism*; D012119:Respiration; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D002087:Butyrates; D002250:Carbon Radioisotopes; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010647:Phenyl Ethers; D011134:Polysaccharides; D011773:Pyruvates; D014280:Triglycerides; D002245:Carbon Dioxide; D002784:Cholesterol; D000535:Aluminum; D002994:Clofibrate